Limited effectiveness for the therapeutic blockade of interferon   in systemic lupus erythematosus: a possible role for type III interferons

Sifalimumab, a Human Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study

(2013) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Emerging therapies for systemic lupus erythematosus — Focus on targeting interferon-alpha

(2012) Eben I. Lichtman et al.   CLINICAL IMMUNOLOGY

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon   monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

(2011) J. T. Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

Profiling the expression of interleukin (IL)-28 and IL-28 receptor α in systemic lupus erythematosus patients

(2011) Shih-Chang Lin et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity

(2011) Qian Wu et al.   ARTHRITIS RESEARCH & THERAPY

Interferon-Lambda: A New Addition to an Old Family

(2010) Raymond P. Donnelly et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Mechanisms of Type III Interferon Expression

(2010) Marie B. Iversen et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Expression of Type III Interferon (IFN) in the Vaginal Mucosa Is Mediated Primarily by Dendritic Cells and Displays Stronger Dependence on NF- B than Type I IFNs

(2010) M. B. Iversen et al.   JOURNAL OF VIROLOGY

IFN-Lambda (IFN-λ) Is Expressed in a Tissue-Dependent Fashion and Primarily Acts on Epithelial Cells In Vivo

(2008) Caroline Sommereyns et al.   PLoS Pathogens